Navigation Links
Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease
Date:4/1/2009

NEW YORK, April 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced that it would make up to $6.5 million in total funding available under three Critical Challenges research programs designed to accelerate solutions to some of the most difficult hurdles standing in the way of breakthrough therapeutics for PD.

The Critical Challenges funding opportunities focus research efforts on key priority areas in Parkinson's disease drug development. Priority challenges are chosen based on their relevance for addressing broader Foundation goals: define Parkinson's disease and its progression, alter the disease course and reduce its symptoms. The first 2009 Challenges are:

  • Clinicopathological Correlations of Parkinson's Disease will drive projects to understand the clinicopathological correlates of Parkinson's disease using extensive clinical data and postmortem tissue from normal control, PD and related disease subjects. Applicants will collaborate with the Arizona Parkinson's Disease Consortium, an existing MJFF grantee that has developed an exceptional bank of well-characterized postmortem tissue and associated clinical data.
  • Understanding LRRK2 Biology seeks proposals with potential to alter disease course by increasing understanding of the role of the gene LRRK2 in Parkinson's disease and developing essential tools to facilitate and accelerate research and therapeutic development efforts around this promising new therapeutic target. Ideal proposals will work to shed light on critical questions surrounding LRRK2, such as how LRRK2 pathogenic mutations directly lead to in vivo functional and pathological outcomes, and which cellular pathways LRRK2 normally and/or abnormally functions in.
  • Postural Instability and Gait Disorders will drive efforts to better treat PD symptoms by clarifying the pathophysiology and biological correlates of posture and gait dysfunction, which patients report to be one of the most debilitating aspects of living with PD, and which is not well-managed by currently available therapies.

"Through the Critical Challenges programs, MJFF targets research that we believe to have critical relevance to the entire field," said Katie Hood, CEO. "Our in-house research staff, in consultation with the Foundation's scientific advisors, designs each Challenge to address a specific priority area where our funding and expertise can make the greatest difference in speeding scientific developments toward the clinic and patients."

Critical Challenges complement the Foundation's annually recurring Pipeline Programs, which do not identify a specific research priority area to be pursued, but instead provide opportunities for projects at various stages of development to be funded, ensuring that new ideas continue flowing into Parkinson's research. Last November, MJFF announced $11 million in 2009 Pipeline Program funding.

Abbreviated information on the 2009 Critical Challenges follows. Full details are available at www.michaeljfox.org/research.cfm.

Clinicopathological Correlations of Parkinson's Disease 2009

Total available funding: $1.5 million

Deadline: 6 p.m. ET, Tuesday, May 19, 2009

Funding Anticipated: December 2009

Postural Instability and Gait Disturbances 2009

Total available funding: $2 million

Deadline: 6 p.m. ET, Friday, June 5, 2009

Funding Anticipated: December 2009

Understanding LRRK2 Biology 2009

Total available funding: $3 million

Deadline: 6 p.m. ET, Monday, June 1, 2009

Funding Anticipated: December 2009

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016 Global and ... a basic overview of the industry that covers ... surgical mesh report explores into the international and ... report on Surgical Mesh market spread across 150 ... and figures is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)... 2, 2016  Deerfield announced today it led ... Vision, Inc. Graybug Vision is an early stage ... transform care for ocular diseases including wet age-related ... was first developed at Johns Hopkins University and ... Graybug Vision is developing ophthalmology ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 2016 , ... Somnoware Healthcare Systems , an innovative ... secured $9 million in Series A funding led by TransLink Capital, with participation ... by Somnoware to further fulfill its mission to connect, organize and analyze clinical ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to return to the esteemed Quaker Ridge Golf Club in Scarsdale, New York ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... replacement patients. The plush design enhances comfort and enables the patient to enjoy ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Spiritual Care ... recognize chaplains for their valuable support to patients and their families, and their overall ... , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” cards with ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy (CAET) will ... time saving and planning tools to attendees and exhibitors for the 2016 WOCN ...
Breaking Medicine News(10 mins):